Lorcaserin

ApprovedSmall molecule

Lorcaserin is a small molecule that works as a Serotonin 2c (5-Ht2c) Receptor Agonist.[2] It is being used across 19 indications, with its most advanced program in Approved.[1]

Lorcaserin is one of 479 small molecule programs targeting Cardiovascular Disease. It is currently in Approved.

Indications

Total Trials

Active Trials

478

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cardiovascular DiseaseActive, not recruiting

Nicotine DependenceActive, not recruiting

Myoclonic EpilepsyActive, not recruiting

Peripheral NeuropathyActive, not recruiting

Kidney DiseaseActive, not recruiting

Cocaine DependenceActive, not recruiting

Weight LossActive, not recruiting

Opioid DependenceActive, not recruiting

Diabetes MellitusActive, not recruiting

Drug DependenceActive, not recruiting

Cardiovascular DiseasePhase 1

Active, not recruiting

Nicotine DependencePhase 2

Active, not recruiting

Myoclonic EpilepsyPhase 3

Active, not recruiting

Peripheral NeuropathyPhase 1

Active, not recruiting

Kidney DiseasePhase 1

Active, not recruiting

Cocaine DependencePhase 2

Active, not recruiting

Weight LossPreclinical

Active, not recruiting

Opioid DependencePhase 1

Active, not recruiting

Diabetes MellitusPhase 3

Active, not recruiting

Drug DependencePhase 1

Active, not recruiting

Showing 10 of 19 indications

Competition

Competitive Landscape

583 competitors in Schizophrenia

#DrugCompanyPhaseTrials

Lorcaserin

Eisai

Approved

1 2

Celexa

AbbVie

Preclinical

4 3

Ozempic

Novo Nordisk

Preclinical

1 4

Resotran

Takeda

Preclinical

1 5

Inapsine

Alnylam Pharmaceuticals

Preclinical

1 6

Zocor

OOrganon and Co

Preclinical

6 7

Depakote

Ibrance

Lunesta

3 10

Comtan

Orion Corporation, Orion Pharma

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cocaine Use Disorder3 trials

Drug Interaction and Self Administration Studies of Compounds for Cocaine Use Disorder

Completed·VVirginia Commonwealth University·Phase 1·NCT02537873·29 enrolled

Phase I Functional Magnetic Resonance Imaging (fMRI) Pharmacodynamic Studies of Compounds for Opioid Use Disorder and Cocaine Use Disorder

Terminated·VVirginia Commonwealth University·Phase 1·NCT03143543·171 enrolled

Lorcaserin in the Treatment of Cocaine Use Disorder

Completed·NNational Institute on Drug Abuse (NIDA)·Phase 2·NCT03007394·272 enrolled

Weight loss2 trials

Lifestyle Modification and Lorcaserin for Weight Loss Maintenance

Completed·UUniversity of Pennsylvania·N/A·NCT02388568·137 enrolled

Lorcaserin for Weight Loss Management in Patients on Antipsychotics: A Pilot Study

Unknown status·SSouthern California Institute for Research and Education·Phase 4·NCT01962402·15 enrolled

Weight Gain2 trials

Addressing Post Cessation Weight Gain

Terminated·MMayo Clinic·Phase 2/3·NCT02412631·84 enrolled

Lorcaserin for Preventing Weight Gain Among Smokers

Completed·MMayo Clinic·Phase 1/2·NCT02393547·20 enrolled

Peripheral Neuropathy2 trials

Lorcaserin in Treating Chemotherapy-Induced Peripheral Neuropathy in Patients With Stage I-IV Gastrointestinal or Breast Cancer

Withdrawn·OOhio State University Comprehensive Cancer Center·Phase 1·NCT04205071

Comparing Lorcaserin Versus Duloxetine for the Treatment of Chemotherapy-Induced Peripheral Neuropathy

Unknown status·—·Phase 2·NCT03812523·50 enrolled

Opioid Use Disorder2 trials

Drug Interaction and Subjective Effects of Compounds for Opioid Use Disorder

Completed·VVirginia Commonwealth University·Phase 1·NCT03143855·32 enrolled

Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder

Completed·NNew York State Psychiatric Institute·Phase 2/3·NCT03169816·60 enrolled

19 more indications

Cannabis Use Disorder2 trials

Lorcaserin for Cannabis Use Disorder

Terminated·NNew York State Psychiatric Institute·Phase 1·NCT03637842·5 enrolled

Use of a Mobile Health Sensor in an Open Label Trial of Lorcaserin for the Treatment of Cannabis Use Disorder

Completed·NNew York State Psychiatric Institute·Phase 1·NCT02932215·17 enrolled

Smoking Cessation2 trials

Mechanisms of Lorcaserin for Smoking Cessation

Terminated·TThe Mind Research Network·Phase 2·NCT04396834·3 enrolled

Combination Nicotine Patch / Lorcaserin for Smoking Cessation

Completed·—·Phase 2·NCT02906644·97 enrolled

Interaction2 trials

Gene-by-Stress Interactions in Intervention Studies Significance

Terminated·—·Phase 1·NCT03011645·7 enrolled

Study to Assess Potential Interactions Between Intravenous Cocaine and Oral Lorcaserin

Completed·NNational Institute on Drug Abuse (NIDA)·Phase 1·NCT02393599·20 enrolled

Dravet syndrome2 trials

Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies

Available· Eisai logo

Eisai··NCT04457687

A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome

Terminated· Eisai logo

Eisai·Phase 3·NCT04572243·22 enrolled

Weight Management2 trials

Low Level Laser Treatment (LLLT) and Lorcaserin for Weight Management

Completed·MMayo Clinic·Phase 3·NCT02129608·44 enrolled

Lorcaserin: Real World Experience in an Insurance-Based Weight Management Clinic

Completed·SScripps Whittier Diabetes Institute··NCT03552107·157 enrolled

Treatment1 trial

Treatment With Lorcaserin for Cocaine Use: The TLC Study

Terminated·GGlenn-Milo Santos·Phase 2·NCT03192995·22 enrolled

Hepatic Impairment1 trial

Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment

Completed· Eisai logo

Eisai·Phase 1·NCT00828932·24 enrolled

Muscle weakness1 trial

Evaluating Muscle Weakness Improvement With Lorcaserin in ICU

Terminated·JJohns Hopkins University·Phase 1/2·NCT02523690·5 enrolled

Cocaine Dependence1 trial

Rebalancing the Serotonergic System in Cocaine Dependence

Withdrawn·MMclean Hospital·Phase 1·NCT03266939

Alcohol Use Disorder1 trial

Laboratory Screening of Lorcaserin for Alcohol Use Disorder

Terminated·TThe Mind Research Network·Phase 2·NCT04396847·5 enrolled

Fed1 trial

Pharmacokinetic Properties of Lorcaserin in the Fed and Fasted State

Completed· Eisai logo

Eisai·Phase 1·NCT00828724·24 enrolled

Renal Impairment1 trial

Pharmacokinetic Properties of Lorcaserin in Subjects With Renal Impairment

Completed· Eisai logo

Eisai·Phase 1·NCT00828438·40 enrolled

Diabetes Mellitus1 trial

BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus

Completed· Eisai logo

Eisai·Phase 3·NCT00603291·604 enrolled

Obesity1 trial

BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management

Completed· Eisai logo

Eisai·Phase 3·NCT00603902·4,008 enrolled

AIN1 trial

Lorcaserin Intra Venous Cocaine Effects

Unknown status·MMidwest Biomedical Research Foundation·Phase 1/2·NCT02680288·32 enrolled

Withdrawal1 trial

Effect of Lorcaserin on Cannabis Withdrawal and Self-administration

Completed·NNew York State Psychiatric Institute·Phase 1/2·NCT03253926·15 enrolled

Overweight1 trial

Pharmacokinetic Properties of Lorcaserin in Obese or Overweight Elderly Subjects

Completed· Eisai logo

Eisai·Phase 1·NCT00828581·24 enrolled

Schizophrenia1 trial

MEtformin and Lorcaserin for WeighT Loss in Schizophrenia

Terminated·UUniversity of North Carolina, Chapel Hill·Phase 4·NCT02796144·71 enrolled

Obese Adolescents1 trial

Single Dose Study to Determine the Safety, Tolerability, and Pharmacokinetic Properties of Lorcaserin Hydrochloride (BELVIQ) in Obese Adolescents From 12 to 17 Years of Age

Completed· Eisai logo

Eisai·Phase 1·NCT02022956·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 35 trial records for Lorcaserin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lorcaserin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lorcaserin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eisai company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Serotonin 2c (5-Ht2c) Receptor Agonist[2]
Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Eisai

Lorcaserin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cocaine Use Disorder3 trials

Weight loss2 trials

Weight Gain2 trials

Peripheral Neuropathy2 trials

Opioid Use Disorder2 trials

Cannabis Use Disorder2 trials

Smoking Cessation2 trials

Interaction2 trials

Dravet syndrome2 trials

Weight Management2 trials

Treatment1 trial

Hepatic Impairment1 trial

Muscle weakness1 trial

Cocaine Dependence1 trial

Alcohol Use Disorder1 trial

Fed1 trial

Renal Impairment1 trial

Diabetes Mellitus1 trial

Obesity1 trial

AIN1 trial

Withdrawal1 trial

Overweight1 trial

Schizophrenia1 trial

Obese Adolescents1 trial

References

Drug Info

Quick Facts

Related News